Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 0.35 |
| ▸ | CNR2 | P34972 | 12/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21720048 | 0.81 | CNR2 (0.33) | CNR1CNR2KDM4ETP53CYP3A4 | |
| SCHEMBL26850294 | 0.81 | CNR2 (0.33) | CNR1CNR2KDM4ETP53CYP3A4 | |
| SCHEMBL21719608 | 0.79 | KDM4E (0.30) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL21719618 | 0.79 | GGPS1 (0.33) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL21719762 | 0.79 | SMPD1 (0.30) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL21720049 | 0.79 | CCNB2 (0.33) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL21720043 | 0.78 | KDM4E (0.40) | CNR1CNR2KDM4ETP53CYP3A4 | |
| SCHEMBL21969698 | 0.78 | — | — | |
| SCHEMBL21885502 | 0.78 | ALDH1A1 (0.32) | CNR1CNR2KDM4ETSHR | |
| SCHEMBL24066947 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889571-B2 | Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias | Terns, Inc. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200087283-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. (US) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087283-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | CNR1 4740/4885CNR2 4682/4885NR1H4 3511/4885 |
| US-10889571-B2 | Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias | ABL1, ABL2, BCR | CNR1 4256/4885CNR2 4035/4885NR1H4 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.